Original Article

Neutrophil/lymphocyte ratio and mean platelet volume in branch retinal vein occlusion

Esla Turkseven Kumral; Nursal Melda Yenerel; Nimet Yesim Ercalik; Serhat Imamoglu; Ece Turan Vural

Abstract

Purpose: To evaluate the mean platelet volume (MPV) and the neutrophil/lymphocyte ratio (NLR) in patients with branch retinal vein occlusion (BRVO).

Methods: Thirty patients with branch retinal vein occlusion (BRVO group) and 27 age and sex matched subjects (control group) were included in the study. MPV and NLR parameters obtained from peripheral blood were recorded.

Results: The mean age was 62.6 ± 12.3 years in BRVO and 63.5 ± 8.2 years in control group. The BRVO group consisted of 13 males and 17 females and the control group included 12 male and 15 female subjects. The mean MPV values were 8.64 ± 2.01 fL in BRVO group and 8.5 ± 1.26 fL in control group. NLR was 2.24 ± 0.79 and 1.89 ± 0.64 in BRVO and control groups respectively. The difference between two groups in terms of MPV and NLR was not statistically significant.

Conclusion: MPV and NLR were found to be not affected in branch retinal vein occlusion patients.

Keywords: Mean platelet volume, Neutrophil/lymphocyte ratio, Retinal vein occlusion

Introduction

Diabetic retinopathy is the most common retinal vasculopathy. Retinal vein occlusions (RVO) make up the second most common category. It is estimated that 16.4 (95% CI 13.9–18.9) million people in the world have RVO. Branch retinal vein occlusions (BRVO) constitute 69.5% of the RVOs. Although the pathogenesis of RVO is not clearly understood, it is believed that Principles of Virchow’s triad for thrombogenesis including abnormalities of the vessel wall, alterations in the blood, and alterations in the blood flow are responsible. Degenerative changes in the vessel walls seem to be the most important one and primarily arteriovenous crossings are the sites of occlusion. Only 4.9% of cases have an occlusion other than an arteriovenous crossing and some other factors such as inflammation (e.g., in sarcoidosis) are thought to be responsible. Hypertension, diabetes mellitus, dyslipidemia, cigarette smoking, cardiovascular and renal disease are the risk factors for BRVO.

Neutrophil/lymphocyte ratio (NLR) and mean platelet volume (MPV) as inflammatory markers recently became popular because of their simplicity, cost effectiveness and their advantages to predict clinical prognosis of specific diseases. Platelets have an important role in the pathogenesis of thrombo-occlusive diseases. Alterations in the platelet function and morphology are determined primarily during or before the fragmentation of their precursor cell (megakaryocyte). Megakaryocyte development has a correlation with the process of nuclear polyploidization. Ploidy may change with platelet consumption and destruction. As megakaryocyte ploidy increases, larger and more active platelets are produced.
thrombogenic factors. MPV is an indicator of platelet size and activation. Ozkan et al. found a relationship between myocardial infarction and MPV values. Thrombosis and inflammatory processes, these inflammatory markers could help us to predict the risk of RVO. In this study we aimed to investigate a link between NLR and MPV parameters and BRVO.

This study is adhered to the tenets of Helsinki and was approved by the Institutional Review Board of the Department of Ophthalmology, Haydarpasa Numune Training and Research Hospital, Turkey, and informed consent was obtained to participate in the study.

Materials and methods

Thirty patients with recently diagnosed branch retinal vein occlusion (BRVO group) and 27 age and sex matched subjects (control group) were included in the study. All patients underwent full ophthalmologic evaluation including best corrected visual acuity, pupillary reactions, intraocular pressure measurement, biomicroscopic and fundoscopic examination. Hemorrhages, cotton wool-spots, edema, and venous dilatation and tortuosity arise from arteriovenous crossing seen in a localized retinal area was diagnosed as branch retinal vein occlusion. Patients with signs of an acute stage of BRVO within a week and no history of previous treatment were included in the study.

All patients with BRVO had systemic hypertension that was under control by medication. Patients with glaucoma, diabetes, systemic inflammatory diseases, cardiovascular, hepatic and renal disorders, blood dyscrasias, and malignancy were excluded from the study. History of routine anti-inflammatory drug usage, oral contraceptives and anti-coagulants, smoking and alcohol consumption was also included in exclusion criteria as they might affect thrombosis.

Blood samples for complete blood count (CBC) were obtained between 08:00 and 9:00 a.m. after overnight fasting from the antecubital vein. Venous blood (1.8 ml) was collected and mixed with 0.2 ml 3.8% sodium citrate solution and analyzed within 2 h after sampling with Cell-Dyn 3700 Hematology Analyzer (Cell-Dyn 3700, Abbott Diagnostics, Abbott Park, IL, USA). It performs simultaneous laser and impedance measurements. The NLR was calculated by dividing the neutrophil count by the lymphocyte count and MPV increases, NLR increases too. They claimed that inflammatory processes have an important role in the pathogenesis of BRVO. Etfal et al. found that NLR as an inflammatory marker increases in venous thromboembolism (VTE) and as the extent of VTE increases, NLR increases too. They claimed that inflammatory processes have an important role in prothrombotic state in patients with VTE. MPV is thought to be a marker of platelet activation. It increases with active and large platelets and is used as laboratory test to predict some occlusive diseases. Elevated MPV was found in silent cerebral infarction that may be an indicator of transient ischemic attack or clinically undetectable stroke. Also, increased MPV is linked with diseases

Results

The BRVO group consisted of 13 male and 17 female patients and the control group included 12 male and 15 female subjects. The mean age of the BRVO group was 62.60 ± 12.3 years and the control group was 63.50 ± 8.20 years. There was not a statistically significant difference between groups with regard to age and sex. The mean MPV values were 8.64 ± 2.01 fL in BRVO group and 8.5 ± 1.26 fL in control group. The difference between two groups was not statistically significant (p = 0.10, p > 0.05). NLR was 2.24 ± 0.79 and 1.89 ± 0.64 in BRVO and control groups respectively. Statistically significant difference was not found between two groups (p = 0.30, p > 0.05). There was no statistically significant difference in platelet count and PCT between groups (Table 1). There was also no statistically significant difference between groups in terms of MPV categories (Table 2).

Discussion

We investigated the importance of MPV and NLR values in branch retinal vein occlusion and did not find any difference in MPV and NLR values between BRVO and control group. Retinal vein occlusion is the most common retinal vascular pathology after diabetic retinopathy. BRVO is more common than CRVO. It is estimated that 5.6 times as many persons are affected by BRVO compared to CRVO. It is believed that cascades of thrombosis and inflammation play role in the pathogenesis of BRVO.

Some studies reported the relation between retinal vein occlusion and thrombotic diseases such as hyperhomocysteinemia, factor V Leiden mutation, deficiency in protein C or S, and anticardiolipin antibodies. Systemic inflammatory diseases are also involved in the pathogenesis of retinal vein occlusion such as sarcoidosis and Behçet’s disease. MPV and NLR are inflammatory markers for the diseases related to thrombosis and inflammation. Etfal et al. found that NLR as an inflammatory marker increases in venous thromboembolism (VTE) and as the extent of VTE increases, NLR increases too. They claimed that inflammatory processes have an important role in prothrombotic state in patients with VTE. MPV is thought to be a marker of platelet activation. It increases with active and large platelets and is used as laboratory test to predict some occlusive diseases. Elevated MPV was found in silent cerebral infarction that may be an indicator of transient ischemic attack or clinically undetectable stroke. Also, increased MPV is linked with diseases

Statistical analysis

Statistical analysis was done by SSPS statistical software (SPSS for windows 17.0, Inc., Chicago, IL, USA). Parametric Student’s t-test and nonparametric Mann-Whitney’s U test were used for comparison of independent groups. Data were reported as mean ± standard deviation (±SD). A level of P < 0.05 was considered significant.

Table 1. Comparison of laboratory data between BRVO and control group.

|                      | BRVO (n = 30) | Control (n = 27) | P  |
|----------------------|--------------|-----------------|----|
| Hb (g/dL)            | 13.35 ± 1.22 | 12.78 ± 1.15    | 0.10|
| Htc (%)              | 39.56 ± 3.21 | 38.57 ± 3.48    | 0.31|
| Plt (K/μL)           | 268.27 ± 57.13 | 247.69 ± 54.85 | 0.21|
| Ptc                  | 0.23 ± 0.06  | 0.21 ± 0.06     | 0.13|
| MPV (fL)             | 8.64 ± 2.01  | 8.5 ± 1.26      | 0.10|
| NLR                  | 2.24 ± 0.79  | 1.89 ± 0.64     | 0.30|

Hb, hemoglobin; Htc, hematocrit; Plt, platelet count; Pct, platelet crit; SD, standard deviation; p > 0.05.
Table 2. Comparison of BRVO and control group by categories of mean platelet volume.

| Categories of MPV (fl) | Groups         | Mean ± SD  | p     |
|------------------------|----------------|------------|-------|
| MPV < 9.5              | BRVO (n = 18)  | 7.84 ± 0.77| 0.57  |
|                        | Control (n = 22)| 7.89 ± 0.71|       |
| MPV > 9.5              | BRVO (n = 12)  | 10.63 ± 0.71| 0.80  |
|                        | Control (n = 5)| 10.45 ± 0.17|       |

BRVO, branch retinal vein occlusion; MPV, mean platelet volume; SD, standard deviation; p > 0.05.

References

1. Wong TY, Scott IU. Retinal vein occlusion. N Engl J Med 2010;363:2135–44.
2. Rogers S, Mc Intosh RL, Journ BGD, Cheung N, Lim L, Wang JJ, et al. International disease consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010;117:313–9.
3. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. Arch Ophthalmol 1996;114:1243–7.
4. Gutmann FA. Evaluation of a patient with central retinal vein occlusion. Ophthalmology 1983;90:481–3.
5. Vine AK, Samama MM. The role of abnormalities in the anticoagulant and fibrinolytic systems in retinal vascular occlusions. Surv Ophthalmol 1993;37:283–92.
6. Weinberg D, Dodwell DG, Fern SA. Anatomy of arteriovenous crossings in branch retinal vein occlusion. Am J Ophthalmol 1990;109:298–302.
7. Beaumont PE, Kang HK. Clinical characteristics of retinal venous occlusions occurring at different sites. Br J Ophthalmol 1986;6:572–80.
8. Ohara K, Okubo A, Sasaki H, Kamata K. Branch retinal vein occlusion in a child with ocular sarcoïdosis. Am J Ophthalmol 1995;119:801–2.
9. Turello M, Pasca S, Daminato R, Delo Russo P, Giacomello R, Venturelli, et al. Retinal vein occlusion: evaluation of ‘classic’ and ‘emerging’ risk factors and treatment. J Thromb Thrombolysis 2010;29:459–64.
10. Bakirci EM, Topcu S, Kalkan K, Tanboga IH, Borecki A, Sevimli S, et al. The role of the nonspecific inflammatory markers in determining the anatomic extent of venous thromboembolism. Clin Appl Thromb Hemost 2015;21(2):181–5.
11. Brown AS, Hong Y, de Belder A, Beacon H, Beeso J, Sherwood R, et al. Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis. Arterioscler Thromb Vasc Biol 1990;10:451–4.
12. Browning DJ. Retinal vein occlusions: evidence based management 2012;33–7 chapter 2.
13. Martin JF. The relationship between megakaryocyte ploidy and platelet volume. Blood Cells 1989;15:108–17.
14. Ozkan B, Uysal OK, Duran M, Sahin DY, Elbasan Z, Tekin K, et al. Relationship between mean platelet volume and atherosclerosis in young patients with ST elevation myocardial infarction. Angiology 2013;64:371–4.
15. Rudiger A, Burckhardt OA, Harpes P, Muller SA, Follath F. The relative lymphocyte count on hospital admission is a risk factor for long-term mortality in patients with acute heart failure. Am J Emerg Med 2006;24:451–4.
16. The Branch Retinal Vein Occlusion Study Group. Argon laser photoacoagulation for macular edema in branch retinal vein occlusion. Am J Ophthalmol 1984;98:271–81.
17. Browning DJ. Retinal vein occlusions: evidence based management 2012;33–7 chapter 2.
18. Chua B, Kifley A, Wong TY, Mitchell P. Homocysteine and retinal vein occlusion: a population based study. Am J Ophthalmol 2015;159:181–2.
19. Grienier B, Hafner G, Dick B, Peetz D, Pfeiffer N. Retinal vascular occlusion and deficiencies in the protein C pathway. Am J Ophthalmol 1999;128:69–74.
20. Janssen MC, ten Heijer M, Wollersheim H, Bredie SJ. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombopholic factors. Thromb Haemost 2005;93:1021–6.
21. Ohara K, Okubo A, Sasaki H, Kamata K. Branch retinal vein occlusion in a child with ocular sarcoïdosis. Am J Ophthalmol 1995;119:801–2.
22. El FL, Khaldi N, Hmaied W, Ksantini I, Mestiri A, Doggi M. Retinal venous occlusion in Behcet’s disease. La Revue Medine Internne 2007;28:742–5.
23. Li B, Liu X, Cao ZG, Li Y, Liu TM, Wang RT. Elevated mean platelet volume is associated with silent cerebral infarction. Int Med J 2014;44(7):653–7.
24. Kay M, Yarlioglu M, Gunebakmaz O, Gunturk E, Inanc T, Dogan A, et al. Platelet activation and inflammatory response in patients with non-dipper hypertension. Atherosclerosis 2010;209:278–82.

Conflict of interest

The authors declared that there is no conflict of interest.
25. Papanas N, Symeonidis G, Maltezos E, Mavridis E, Karvageli E, Vosnakidis T, et al. Mean platelet volume in patients with type 2 diabetes mellitus. *Platelets* 2004;15:475–8.

26. Sahin A, Sahin M, Yüksel H, Türkçü FM, Cinar Y, Cingü AK, et al. The mean platelet volume in patients with retinal vein occlusion. *J Ophthalmol* 2013;2013:236371.

27. Onder HI, Klic AC, Kaya M, Bulur S, Onder E, Tunc M. Relation between platelet indices and branch retinal vein occlusion in hypertensive patients. *Indian J Ophthalmol* 2013;61:160–2.

28. Stewart RMK, Clearkin LG. Insulin resistance and autoregulatory dysfunction in glaucoma and retinal vein occlusion. *Am J Ophthalmol* 2008;145:394–6.

29. Rabinowicz IM, Litman S, Michaelson IC. Branch venous thrombosis a pathological report. *Trans Ophthalmol Soc UK* 1969;88:191–210.

30. Christoffersen NLB, Larson M. Pathophysiology and hemodynamics of BRVO. *Ophthalmology* 1999;106:2054–62.

31. Ingerslev J. Thrombophilia: a feature of importance in retinal vein thrombosis? *Acta Ophthalmol Scand* 1999;77:619–21.

32. Ornek N, Ogurel T, Ornek K, Onaran Z. Mean platelet volume in retinal vein occlusion. *Eur Rev Med Pharmacol Sci* 2014;18(19):2778–82, Oct.

33. Yavuz B, Ertugrul DT, Yalcın AA, Kucukazman M, Ata N, Dal K. Increased mean platelet volume in rheumatic mitral stenosis: a possible factor for thromboembolic events. *J Cardiol* 2009;53:204–7.

34. Yilmaz MB, Akin Y, Biyikoglu SF, Guray U, Kisacik HL, Korkmaz S. Left ventricular thrombosis is associated with increased mean platelet volume in patients with dilated cardiomyopathy and sinus rhythm. *Acta Cardiol* 2004;59:41–5.

35. Braekkan SK, Mathiesen EB, Njolstad I, Wilsaa T, Stormers J, Hansen JB. Mean platelet volume is a risk factor for venous thromboembolism: the Tromso study. *J Thromb Haemost* 2010;8:157–62.